GLAXO Statistics

Total Valuation

GlaxoSmithKline Pharmaceuticals has a market cap or net worth of INR 409.15 billion. The enterprise value is 388.19 billion.

Market Cap	409.15B
Enterprise Value	388.19B

Important Dates

The last earnings date was Tuesday, October 29, 2024.

Earnings Date	Oct 29, 2024
Ex-Dividend Date	Nov 7, 2024

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-1.89%
Shares Change (QoQ)	+1.57%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	41.29M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 38.17, with an EV/FCF ratio of 41.29.

EV / Earnings	57.51
EV / Sales	10.90
EV / EBITDA	38.17
EV / EBIT	40.47
EV / FCF	41.29

Financial Position

The company has a current ratio of 1.66, with a Debt / Equity ratio of 0.01.

Current Ratio	1.66
Quick Ratio	1.31
Debt / Equity	0.01
Debt / EBITDA	0.01
Debt / FCF	0.02
Interest Coverage	554.80

Financial Efficiency

Return on equity (ROE) is 42.03% and return on invested capital (ROIC) is 36.91%.

Return on Equity (ROE)	42.03%
Return on Assets (ROA)	17.09%
Return on Capital (ROIC)	36.91%
Revenue Per Employee	11.09M
Profits Per Employee	2.10M
Employee Count	3,211
Asset Turnover	1.01
Inventory Turnover	2.62

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +45.28% in the last 52 weeks. The beta is 0.22, so GlaxoSmithKline Pharmaceuticals's price volatility has been lower than the market average.

Beta (5Y)	0.22
52-Week Price Change	+45.28%
50-Day Moving Average	2,664.22
200-Day Moving Average	2,460.74
Relative Strength Index (RSI)	35.05
Average Volume (20 Days)	94,923

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, GlaxoSmithKline Pharmaceuticals had revenue of INR 35.60 billion and earned 6.75 billion in profits. Earnings per share was 39.84.

Revenue	35.60B
Gross Profit	21.76B
Operating Income	9.59B
Pretax Income	9.29B
Net Income	6.75B
EBITDA	9.99B
EBIT	9.59B
Earnings Per Share (EPS)	39.84

Full Income Statement

Balance Sheet

The company has 21.11 billion in cash and 147.90 million in debt, giving a net cash position of 20.96 billion.

Cash & Cash Equivalents	21.11B
Total Debt	147.90M
Net Cash	20.96B
Net Cash Per Share	n/a
Equity (Book Value)	16.73B
Book Value Per Share	97.18
Working Capital	12.01B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 9.71 billion and capital expenditures -312.22 million, giving a free cash flow of 9.40 billion.

Operating Cash Flow	9.71B
Capital Expenditures	-312.22M
Free Cash Flow	9.40B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 61.12%, with operating and profit margins of 26.94% and 18.96%.

Gross Margin	61.12%
Operating Margin	26.94%
Pretax Margin	26.10%
Profit Margin	18.96%
EBITDA Margin	28.07%
EBIT Margin	26.94%
FCF Margin	26.40%

Dividends & Yields

GlaxoSmithKline Pharmaceuticals does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	80.23%
Buyback Yield	1.89%
Shareholder Yield	1.89%
Earnings Yield	1.65%
FCF Yield	n/a

Dividend Details

Stock Splits

The last stock split was on September 11, 2018. It was a forward split with a ratio of 2.

Last Split Date	Sep 11, 2018
Split Type	Forward
Split Ratio	2

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a